Henry Jemil Esber

Henry Jemil Esber has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Seelos Therapeutics, Inc., Innovus Pharmaceuticals, Inc. and NANOMIX Corp. We count 27 filings; the first trade dates from 11 January 2010 and the latest from 23 November 2017.

No open-market sale appears; the market trades are 4 purchases worth €9,563. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 17 share grants. Since January 2017: 3 purchases and no sales on the market.

In size, the median ticket on the buying side is €1,056. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 27 November 2017 with an open-market purchase (€7,054) in Innovus Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.